These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30175400)

  • 41. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Agarwal R; Dawson MA; Dreyling M; Tam CS
    Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 47. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
    Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
    Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
    Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
    Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
    Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
    Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
    Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X; Inghirami G; DiLiberto M; Chen-Kiang S; Leonard JP
    Blood; 2019 Mar; 133(11):1201-1204. PubMed ID: 30692121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
    Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Zhang L; Baher L; Cheng M; Lee D; Beaupre DM; Rule S
    Blood; 2015 Aug; 126(6):739-45. PubMed ID: 26059948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
    Tivey A; Shotton R; Eyre TA; Lewis D; Stanton L; Allchin R; Walter H; Miall F; Zhao R; Santarsieri A; McCulloch R; Bishton M; Beech A; Willimott V; Fowler N; Bedford C; Goddard J; Protheroe S; Everden A; Tucker D; Wright J; Dukka V; Reeve M; Paneesha S; Prahladan M; Hodson A; Qureshi I; Koppana M; Owen M; Ediriwickrema K; Marr H; Wilson J; Lambert J; Wrench D; Burney C; Knott C; Talbot G; Gibb A; Lord A; Jackson B; Stern S; Sutton T; Webb A; Wilson M; Thomas N; Norman J; Davies E; Lowry L; Maddox J; Phillips N; Crosbie N; Flont M; Nga E; Virchis A; Camacho RG; Swe W; Pillai A; Rees C; Bailey J; Jones S; Smith S; Sharpley F; Hildyard C; Mohamedbhai S; Nicholson T; Moule S; Chaturvedi A; Linton K
    Blood Adv; 2024 Mar; 8(5):1209-1219. PubMed ID: 38127279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
    Soumerai JD; Diefenbach CS; Jagadeesh D; Asch A; Kumar A; Tsai ML; Jandl TA; Lossos IS; Kenkre VP; Awan F; Novotny W; Huang J; Miao L; Rajagopalan P; Ghalie RG; Zelenetz AD
    Br J Haematol; 2024 May; 204(5):1762-1770. PubMed ID: 38500476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.